logo
Lucidly Launches A New Platform to Redefine Website Proofing and Collaboration

Lucidly Launches A New Platform to Redefine Website Proofing and Collaboration

Lucidly, a new platform for visual review and collaboration, is launching to streamline how creative agencies and freelancers review websites. Lucidly makes it easy to leave comments, track feedback, and manage QA all in one place and in real-time.
AKRON, OH / ACCESS Newswire / July 26, 2025 / Lucidly today announced the official launch of its all-in-one visual feedback and task collaboration platform designed for agencies, freelancers, and product teams working on web projects. The new platform streamlines website proofing and quality assurance workflows by combining visual commenting with built-in task tracking.
Lucidly offers users a unified space to leave visual comments directly on live websites and manage those comments as actionable tasks in real time. This allows teams to collaborate more efficiently, stay organized, and reduce the need for separate project management tools.
Key platform features include:
Collaborator Flexibility - All plans support unlimited team and client collaborators with no additional user fees, reducing friction for growing teams.
Agency-Centered Design - Built specifically for creative and technical service providers, Lucidly emphasizes speed, usability, and focused functionality without unnecessary complexity.
User-Friendly Interface - A clean and intuitive layout ensures clients and stakeholders can participate in reviews without technical experience or onboarding time.
Reliable Support and Responsiveness - The Lucidly team resolves over 99% of reported issues within 24-72 hours and regularly incorporates customer feedback into product updates.
Simple, Transparent Pricing - Monthly plans begin at $9, with higher tiers offering expanded capabilities at competitive rates.
Lucidly aims to serve as a practical solution for teams seeking a focused, affordable way to manage web feedback cycles without relying on multiple disconnected tools. The platform is now available to new users, with a 10-day free trial and optional lifetime access packages currently being offered.
About Lucidly
Lucidly is a software company based in Akron, Ohio, focused on building simple, effective tools for design and development teams. Its flagship platform provides a streamlined way to capture, organize, and act on website feedback in real time.
Media Contact
Organization: Lucidly
Contact Person Name: Shane Gauthier
Website: https://www.lucidly.so/
Email: [email protected]
City: Akron
State: OH
Country: United States
SOURCE: Lucidly
press release
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio

CONMED (CNMD) Q2 Earnings: What To Expect
CONMED (CNMD) Q2 Earnings: What To Expect

Yahoo

time18 minutes ago

  • Yahoo

CONMED (CNMD) Q2 Earnings: What To Expect

Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store